COMPARE · Reviewed August 3, 2026
ADUS vs UHS
Verdict: Side-by-side breakdown using the Bull Rankings model. ADUS scored 75.1, UHS scored 70.4 — ADUS leads.
Compare another set
ADUS
Addus HomeCare Corporation
75.1
$115.22 · $2.2B
fundamentals as of
Score gap
4.7
ADUS leads
UHS
Universal Health Services, Inc.
70.4
$166.06 · $10.1B
fundamentals as of
The model, pillar by pillar (0–100 each)
ADUS
stronger →← stronger
UHS
57
Qualityreturns · margins · balance sheet
69
96
Growthrevenue & earnings expansion
61
77
Valuevaluation vs sector peers
83
UHS is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ADUS
UHS
$137mC
FCF
$913mC+
+19.6%B+
Rev
+10.4%B
0.12B+
D/E
0.69C+
21.3xB+
P/E
6.8xA
1.11B+
PEG
1.20B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ADUS
UHS
13% below
Price vs fair valuelower is cheaper
28% below
~2%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-3%/yr
+9%
1-yr DCF upside
+32%
+15%
5-yr DCF upside
+40%
+24%
10-yr DCF upside
+51%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ADUS
No notable signals flagged.
UHS
Why this score
- Buying back stock
The companies
ADUSAddus HomeCare Corporation
Why now
Medical Care Facilities · market cap $2.2b. 7% off the 52-week high of $124.44. Revenue growing +20%, comfortably above the S&P median. 13 sell-side analysts rate this a Buy with a mean 1-yr target of $133.00 (implying +15% upside).
Moat
FCF converts 138% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
UHSUniversal Health Services, Inc.
Why now
Medical Care Facilities · market cap $10.1b. Down 33% from 52-week high of $246.33 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $193.88 (implying +17% upside).
Moat
ROE 20% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 33% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.